Close Menu

NEW YORK – Bristol Myers Squibb announced on Friday that the European Commission approved the combination of its immune checkpoint inhibitors, nivolumab (Opdivo) and ipilimumab (Yervoy), with chemotherapy as a first-line treatment for non-small cell lung cancer patients.

The combination treatment was approved for metastatic NSCLC patients without EGFR or ALK gene mutations and regardless of their PD-L1 status.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.